Cadila Healthcare
Cadila Healthcare
Shareholder Return: 3-year, Sales Growth: 3-year CAGR, Return On Equity: 3-year average
At a Glance
-
Shareholder Return122%
-
Sales Growth10%
-
Return on Equity31 %
Why Super 50
This Ahmedabad-based drugmaker is looking to double its sales in the US, one of its largest markets, to more than $1 billion. The company has a 20-acre consolidated research facility, in addition to multiple research sites and manufacturing plants in India and the US, which have US Food and Drug Administration approvals. Cadila is credited with launching India's first new chemical entities, and it aspires to become a research-led drugmaker by 2020.
